Resonance Health Ltd
Resonance Health Limited is an Australia-based healthcare technology and services company.
The business
Resonance Health Limited is an Australia-based healthcare technology and services company. The Company is engaged in the development and commercialization of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its segments include software-as-medical-device (SaMD), Corporate, Resonance Clinical, and TrialsWest. Its SaMD products incorporate such as Artificial Intelligence (AI) FerriScan, FerriSmart, HepaFatScan, HepaFatSmar, LiverSmart, and CardiacT2. FerriScan is a core-lab product that provides an accurate assessment of liver iron concentration (LIC) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. It operates as the Clinical Trial Research Organisation (CRO) and local sponsor for a major global pharma company's clinical trial in Australia of a new drug compound.
Small Caps Research
No research on Resonance Health Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise RHT based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Resonance Health Partners with UK CRO to Include SaMD Services in Global Clinical Trials
Resonance Health signs 24-month deal with UK CRO Image Analysis to add SaMD MRI endpoints to global trials, targeting obesity and metabolic disease.
Resonance Health Improves Cash Position as Clinical Trial Pipeline Expands
Resonance Health boosts FY26 cash to net $2.3m, receipts $14.3m; pipeline over $12m as MRI liver fibrosis trial recruitment completes.
Resonance Health expands clinical trial operations with Sun Pharmaceutical agreement
Australian healthcare technology and services company Resonance Health (ASX: RHT) has secured an agreement with Sun Pharmaceutical Industries to operate as its local Australian sponsor. As sponsor, Resonance will provide clinical research organisation, trial site and imaging analysis services for the global pharmaceutical giant’s Australian clinical trial of a new drug compound. Resonance estimates it […]
Resonance Health to acquire TrialsWest in $8m deal, expands global clinical trial reach
Perth-based Resonance Health (ASX: RHT) has secured a deal to acquire private clinical trial site and research centre TrialsWest, representing a major step forward in its growth strategy. TrialsWest is one of Australia’s most experienced clinical research centres, partnering with some of the world’s leading pharmaceutical and biotechnology companies to help bring new medicines and […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.